

**GROUPE TECHNOLOGIQUE KDA SIGNS A DEVELOPMENT AGREEMENT
FOR SINGAPORE MARKET**

Thetford Mines, Quebec – March 23, 2022 – KDA Group Inc. (TSXV: KDA) (“**KDA**” or the “**Corporation**”) through its wholly-owned subsidiary, Groupe Technologique Inc. (“**Tech KDA**”), announces the creation of a major partnership with two companies in the medical and pharmaceutical technology industry, thereby launching its international expansion.

An initial CAD \$300,000 agreement between RxMedz (“**RxMedz**”), a wholly-owned subsidiary of Medicell Pharmaceutical (“**Medicell**”) of Singapore, and ZoomMed Médical Inc. (“**ZoomMed**”) for the development of an adapted version of Tech KDA’s KRx e-prescribing platform and the initial deployment in twenty (20) clinics in Singapore, South East Asia. The agreement provides that upon successful completion of the project, RxMedz will acquire the intellectual property and related rights to the customized version of the e-prescriber for CAD \$5 million.

Medicell and its subsidiary RxMedz are fast-growing Singapore-based companies founded by a group of experienced pharmaceutical experts. They have been steadily growing in the esthetic, pharmaceutical, medical device and nutrition sectors of the Asia-Pacific healthcare industry over the past 10 years. Medicell has several distribution networks in Asia Pacific: Singapore, Malaysia, Indonesia, Thailand, Vietnam, Brunei and the Philippines. Additional information about Medicell is available at www.medicellpharma.com.

ZoomMed, on the other hand, builds and operates the ZoomMed communication network, an interoperable network for the exchange of clinical information between physicians and various other healthcare stakeholders, such as pharmacists, specialists, pharmaceutical companies and private insurers. The cornerstone of this network is the ZRx Prescriber, an innovative web-based technology application that greatly simplifies prescription writing for physicians. Since it is a stand-alone product, it can easily be integrated with any electronic medical record application. Additional information about ZoomMed is available at www.zoommed.com.

“With the expertise of the ZoomMed team and Medicell's presence in the Asia Pacific market, we are confident that our solution will appeal to physicians in Southeast Asia with an innovative product that offers all the benefits of our KRx platform, a superior, efficient and indispensable software application for patient benefit, wellness and safety. This partnership is part of our growth strategy and allows us to enter the international market for the first time through Singapore,” said Marc Lemieux, Chief Executive Officer of KDA.

ABOUT KDA GROUP

KDA Group is a leader in technological innovations and specialized solutions in the pharmaceutical market. KDA is a corporation that offers quality products and has a respected expertise among the various stakeholders in the pharmaceutical and medical sectors. Its management team is guided by the vision to pursue leading the way in Canada and internationally. Additional information about the Corporation is available at www.kdagroup.ca and on SEDAR at www.sedar.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

INFORMATION

Marc Lemieux, Chief Executive Officer

514 622-7370

info@groupekda.ca